mizolastine

Mizolastine is a second-generation, non-sedating antihistamine used primarily for the symptomatic relief of allergic rhinoconjunctivitis (hay fever) and urticaria. It acts as a selective antagonist of peripheral histamine H1 receptor, thereby blocking the effects of histamine released during allergic reactions. Mizolastine does not prevent the release of histamine from mast cells but inhibits its binding to H1 receptor, reducing symptoms such as sneezing, runny nose, and itchy skin rashes. The drug is fast-acting with an onset within 1 hour and provides relief for up to 24 hours after administration. It has minimal central nervous system penetration compared to first-generation antihistamines, resulting in fewer sedative side effects[1][2][4][5][6][7][8]. Developed by UCB.

Brand names

Mizollen

Other names

mizolastine